Efficacy of Secukinumab in Chinese Patients with Moderate-to-Severe Hidradenitis Suppurativa: A 16-Week, Single-Center, Prospective, Real-World Study
Chao Wu, Xiao Ma, Yong-jun Wang, Tie-jun Liu, Xin-yuan Zhang, Hong-zhong Jin · 2026
Read Efficacy of Secukinumab in Chinese Patients with Moderate-to-Severe Hidradenitis Suppurativa: A 16-Week, Single-Center, Prospective, Real-World Study by Chao Wu, Xiao Ma, Yong-jun Wang, Tie-jun Liu, Xin-yuan Zhang, Hong-zhong Jin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13573794.txt.
Description
Hidradenitis suppurativa is a painful, recurring skin disease of folds and creases, and one immune signal, IL-17A, drives much of it. Chao Wu and co-authors follow 31 Chinese patients with moderate to severe disease on secukinumab, a drug that blocks that signal. The 16-week study mirrors real clinic practice at one center.
By week 16, about 55 percent of patients hit the standard response mark. Counts of inflamed lumps and draining tunnels fell, and pain and quality-of-life scores improved. Most patients also used other treatments during the study. One blood fat measure, high triglycerides, unexpectedly tracked with better response. Side effects were mild: a few cases of acne, rash, and fever. The authors call the results encouraging for a group with few options.
Catalog record
| CREATOR | Chao Wu, Xiao Ma, Yong-jun Wang, Tie-jun Liu, Xin-yuan Zhang, Hong-zhong Jin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |